Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 232

The DOI matches its Crossref record.

Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses

Open access
Mok, Hoyin, Palmer, Donna J., Ng, Philip, Barry, Michael A.·2005·Molecular Therapy

Abstract

Adenoviruses are robust gene delivery vectors in vivo, but are limited by their propensity to provoke strong innate and adaptive responses. Previous work has demonstrated that polyethylene glycol (PEG) modification of adenovirus can protect the vectors from preexisting and adaptive immune responses by reducing protein-protein interactions. To test whether PEGylation can reduce innate immune responses to adenovirus by reducing their interactions with immune cells, first-generation (FG-Ad) and helper-dependent (HD-Ad) Ad5 vectors were PEGylated with SPA-PEG and tested in vitro and in vivo. We demonstrate that increasing PEGylation ablated in vitro transduction, but surprisingly had no negative effect on the level or distribution of in vivo gene delivery. This poor in vitro transduction could be rescued in part by physically forcing the PEGylated vectors onto cells, suggesting that physiological forces in vivo may enable transduction via heparin sulfate proteoglycan and integrin interactions. While transduction remained the same as for unmodified vectors, the PEGylated vectors reduced innate IL-6 responses by 70 and 50% in vivo for FG-Ad and HD-Ad. These reduced innate responses paralleled similar reductions in vector uptake by macrophages in vitro and Kupffer cells in vivo. These data suggest that PEGylation of Ad vectors can reduce innate immune responses without reducing transduction in vivo. These data also suggest that nonspecific vector uptake by macrophages and Kupffer cells may be critically involved in the initial activation of innate immune responses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2004.09.015

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 31

  1. Schnell, 2001, Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors, Mol. Ther., 3, 708, 10.1006/mthe.2001.0330 · DOI · Paper page
  2. Ben-Gary, 2002, Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes, Mol. Ther., 6, 287, 10.1006/mthe.2002.0658 · doi:10.1006/mthe.2002.0658
  3. Juillard, 1995, Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector, Eur. J. Immunol., 25, 3467, 10.1002/eji.1830251239 · DOI
  4. Hemminki, 2002, Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy, Hum. Gene Ther., 13, 1505, 10.1089/10430340260185139 · doi:10.1089/10430340260185139
  5. Vlachaki, 2002, Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model, Mol. Ther., 6, 342, 10.1006/mthe.2002.0669 · DOI
  6. Varnavski, 2002, Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity, J. Virol., 76, 5711, 10.1128/JVI.76.11.5711-5719.2002 · DOI
  7. Vilquin, 1995, FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer, Hum. Gene Ther., 6, 1391, 10.1089/hum.1995.6.11-1391 · DOI · Paper page
  8. Morsy, 1998, An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene, Proc. Natl. Acad. Sci. USA, 95, 7866, 10.1073/pnas.95.14.7866 · DOI · Paper page
  9. Morral, 1999, Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons, Proc. Natl. Acad. Sci. USA, 96, 12816, 10.1073/pnas.96.22.12816 · DOI · Paper page
  10. Muruve, 2004, Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo, J. Virol., 78, 5966, 10.1128/JVI.78.11.5966-5972.2004 · DOI · Paper page
  11. Brunetti-Pierri, 2004, Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates, Hum. Gene Ther., 15, 35, 10.1089/10430340460732445 · DOI · Paper page
  12. O’Riordan, 1999, PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo, Hum. Gene Ther., 10, 1349, 10.1089/10430349950018021 · DOI · Paper page
  13. Croyle, 2000, Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions, Hum. Gene Ther., 11, 1713, 10.1089/10430340050111368 · DOI
  14. Croyle, 2001, “Stealth” adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung, J. Virol., 75, 4792, 10.1128/JVI.75.10.4792-4801.2001 · DOI · Paper page
  15. Alemany, 2000, Blood clearance rates of adenovirus type 5 in mice, J. Gen. Virol., 81, 2605, 10.1099/0022-1317-81-11-2605 · DOI · Paper page
  16. Beekman, 1997, Synthetic peptide vaccines: palmitoylation of peptide antigens by a thioester bond increases immunogenicity, J. Pept. Res., 50, 357, 10.1111/j.1399-3011.1997.tb01195.x · doi:10.1111/j.1399-3011.1997.tb01195.x
  17. Palmer, 2003, Improved system for helper-dependent adenoviral vector production, Mol. Ther., 8, 846, 10.1016/j.ymthe.2003.08.014 · DOI · Paper page
  18. Smith, 2003, Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice, Hum. Gene Ther., 14, 777, 10.1089/104303403765255165 · DOI · Paper page
  19. Ogawara, 2004, A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo, Hum. Gene Ther., 15, 433, 10.1089/10430340460745766 · DOI
  20. Nakata, 1967, Microcirculation and hemodynamic analysis of the blood circulation of the liver, Acta Pathol. Jpn., 17, 361
  21. Plank, 2003, The magnetofection method: using magnetic force to enhance gene delivery, Biol. Chem., 384, 737, 10.1515/BC.2003.082 · DOI · Paper page
  22. Campos, 2004, Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector, Mol. Ther., 9, 942, 10.1016/j.ymthe.2004.03.006 · DOI
  23. Zsengeller, 1998, Adenovirus-mediated granulocyte–macrophage colony-stimulating factor improves lung pathology of pulmonary alveolar proteinosis in granulocyte–macrophage colony-stimulating factor-deficient mice, Hum. Gene Ther., 9, 2101, 10.1089/hum.1998.9.14-2101 · DOI
  24. Higginbotham, 2002, The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid, Hum. Gene Ther., 13, 129, 10.1089/10430340152712683 · DOI
  25. Alemany, 2001, CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors, Gene Ther., 8, 1347, 10.1038/sj.gt.3301515 · DOI · Paper page
  26. Everett, 2003, Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors, Hum. Gene Ther., 14, 1715, 10.1089/104303403322611737 · DOI
  27. Martin, 2003, Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism, Mol. Ther., 8, 485, 10.1016/S1525-0016(03)00182-5 · DOI
  28. Muruve, 1999, Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo, Hum. Gene Ther., 10, 965, 10.1089/10430349950018364 · DOI · Paper page
  29. Borgland, 2000, Adenovirus vector-induced expression of the C-X-C chemokine IP-10 is mediated through capsid-dependent activation of NF-kappaB, J. Virol., 74, 3941, 10.1128/JVI.74.9.3941-3947.2000 · DOI
  30. Liu, 2003, Molecular basis of the inflammatory response to adenovirus vectors, Gene Ther., 10, 935, 10.1038/sj.gt.3302036 · DOI · Paper page
  31. Davis, 2001, Construction of adenoviral vectors, Mol. Biotechnol., 18, 63, 10.1385/MB:18:1:63 · DOI

Cited by

See all 232

Metadata

Authors
Mok, H., Palmer, D. J., Ng, P., & Barry, M. A.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2005-01
Volume
11
Issue
1
Pages
66-79
ISSN
1525-0016 (ISSN-L)
OpenAlex
W2022429082
Cited by
232
References
0
FWCI
7.75
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. https://app.cochat.ai/papers/10.1016/j.ymthe.2004.09.015
The paper
Mok, H., Palmer, D. J., Ng, P., & Barry, M. A. (2005). Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2004.09.015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.